Abstract

As in many other medical disciplines, a substantial change of paradigms in oncology and oncotherapy can be observed. In particular, for the treatment of solid tumor lesions the former rather rigid approach to differentiate between curative (no detection of distant metastases) and palliative intention (including systemic advancement of tumor disease) has been increasingly overcome. The concept of oligometastases has been getting more and more attention. Oligometastatic status can be classified if in first diagnosis or in follow-up investigation for tumor staging only a few distant metastases are found. According to the former guidelines, this might only lead to initiation of a palliative treatment, in the majority of cases to a systemic type of therapy! Interestingly, there has been substantial evidence that local ablation of the small number of filiae can favorably influence quality of life (the main intent of “palliative care” according to the definition by WHO) and prognosis. However, there are no predictive markers yet such as laboratory parameters, which allow to assess prognosis of a certain tumor stage / disease including oligometastases.

Surgical resection was and is the gold standard of local ablation but only a certain percentage of patients with oligometastases can be approached with surgical intervention since several of them are unresectable from a technical or inoperable from an anesthesiological point of view. In addition to surgical ablation, there have been a number of non- or minimally invasive techniques available such as thermo-, chemo- and radioablading procedures.

This review aims at Brachytherapy (BT) as radioablating method, its indications as part of curative concepts, the possible treatment spectrum shown in detail at the University Hospital of Magdeburg (Germany), and, in particular, indicating what is feasible and achievable from a qualitative and quantitative point of view. Finally, exemplary and representative cases document the potential benefit in radioablation of metastases.

Keywords: Brachytherapy; Radiation Therapy; Interstitial Brachytherapy (IBT); Organs at Risk (OAR); Oncological profile of diagnoses
by radioactive decay, it is called gamma radiation). This radiation has only a short operating range due to the significantly lower amount of energy providing the advantage that during therapeutic procedure, the surrounding organs (called "organs at risk\(\text{[OAR]}\)) can be much better preserved than by a percutaneous radiation mode. On the other hand, BT requires a spatially not much extended rather close distance between radiation source and tumor lesion. To realize this, either special applicators (intraluminal BT), catheters, tubes or hole needles (interstitial BT) needs to be placed or inserted:

- Within or near the tumor lesion (definitive or primary radiotherapy),
- Into a postoperative (former) tumor bed, in existing (hole) spaces/lumens (e.g., esophagus, Bronchus, cervix) (or)
- In case of superficial mucosa or skin tumors, into moulages, which are adhered to the tumor surface?

Via the devices, radioactive source is transferred to or at the tumor lesion using After Loading(AL) procedure after previous 3D-based imaging and precise calculation of the appropriate dos(agi) e. Depending on the dose rate per time, "Low-Dose-Rate" (LDR), "Medium-Dose-Rate" (MDR) or "High-Dose-Rate" (HDR) BT is distinguished. According to this, the duration of the radiation is different, e.g., in “low-risk” prostate cancer encapsulated iodine or palladium seeds can be used as part of a LDR-BT, which provides the effective cumulative dose within only three months. In contrast, HDR-BT takes only several minutes.

Both strategies of radiation (EBRT and BT) have become clinical standard in the mean time. However, BT is used only for a restricted spectrum of indications in the majority of centres, in particular, in gynecological tumor lesions (carcinoma of the vagina, of the endometrium and cervix uteri as well as breast cancer, in the latter case as boost or in cases of local tumor recurrency) and prostate cancer. In addition, BT is also considered a potential standard procedure in superficial end luminal tumor lesions of the bronchial system or the esophagus.

Last but not least, brachytherapy is also part of the therapeutic spectrum for tumor lesions of otorhinolaryngology at several institutions of radiotherapy.

Without dispute, there is no sustainable therapeutic result achievable with no complete resection of the primary tumor lesion or even metastases, and derived from this, surgical resection has a great value in this concept.

In various tumor entities such as cancer of the pharynx, cervix, prostate and anus, it has been shown [15-18] that radiation and a combined radio-/chemotherapy can be considered an equivalent treatment alternative for curation of locally advanced non-metastasized tumor stages.

In case of
- Oligometastasized tumor stage (or)
- Local recurrence of the tumor lesion,

Local clearance of tumor growth can also result in a potential improvement of overall tumor prognosis in addition to a mitigation of tumor-associated symptoms.

For patients who are inoperable and unrespectable due to various reasons, numerous minimally invasive tumor-abladingtherapy modes have been introduced and established in clinical practice [19-21], which broaden the spectrum of available options to treat cancer patients. In this context, Radio Frequence Ablation (RFA) [22-25] as thermoablative or interstitial brachytherapy (iBT) [26-30] as radioablative procedure need to be mentioned.

Taken together, beside oncosurgery as the undisputable gold standard for the treatment of solid tumor lesions in numerous tumor diseases there are effective alternatives and additive procedures.

The common aim is to achieve local tumor control but alternative treatment strategies are mainly used if surgical intervention is not the best choice due to various reasons.

However, there has been no broad consensus yet since for the majority of tumor diseases, prospective studies comparing the various alternative or additive approaches are rather rare.

Therefore, on one hand the novel minimally invasive measures need to be discussed in the interdisciplinary tumor board sessions and to be used adequately according to their therapeutic potential (in particular, if tumor resection is not a reasonable choice) and on the other hand, studies need to be initiated comparing the various therapeutic procedures to gain for appropriate evidence.

By means of modern tomographic imaging, it has become possible to reach almost each tumor lesion by means of a minimally invasive approach using diverse applicators such as catheters or hole needles and, thus, to put brachytherapy into effect.

In particular, for pulmonary and hepatic metastases of colorectal carcinomas and for hepatocellular carcinoma (HCC), effectiveness by radiotherapy modes has been detected with regard to local tumor control and overall tumor prognosis [31-34].

Most likely, indication profile will be extended due to ongoing clinical phase-II studies, e.g.,
- Use of iBT in renal cancer,
- Combination of radiotherapy with systemic therapy in cholangiocarcinoma (or)
- Feasibility and effectivity of a hypo fractionated brachytherapy.

Are investigated (EUDRA-CT 2011-002839-25, EUDRA-CT 2008-001316-21, EUDRA-CT 2009-015419-42).

The aim of the manuscript is based on the overall positive experiences and the recent dynamic development of modern BT to provide an update on the today’s options of this very specific and novel mode of tumor therapy. In particular, it is shown in which indications BT (spectrum of diagnoses) can be reasonably considered in addition to surgical and locally ablative procedures as well as novel concepts can be put into effect at the University Hospital of Magdeburg (Germany) in daily clinical practice. In detail,

1. It is described which specific procedures of BT (methodological profile) are used,
2. It is shown what case numbers can be achieved currently,
Table 1: Chronological overview of representative studies on brachytherapy.

| AUTHOR | Title of publication | Bibliograficdata |
|--------|----------------------|------------------|
| ICRU   | Dose and volume specification for reporting intracavitary therapy in gynecology. | ICRU Report 38 1985; Washington: International Commission on Radiation Units and measurements. |
| Thomas DS, Nauta RJ, Rodgers JE et al. | Intraoperative high-dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. | Cancer 1993; 71: 1977-1981 |
| Takehiro I, Toshikiko I, Teruki T et al. | Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. | Int J Radiat Oncol Biol Phys 1996; 36: 1201-1204 |
| ICRU. | Dose and volume specification for reporting interstitial therapy. | ICRU Report 581997, Bethesda: International Commission on Radiation Units and measurements. |
| Wambersie A, Battermann JJ. | Dose specification and reporting: the ICRU recommendations. | Joain CAP, Flynn A, Hall EJ (eds). Principles and practice of brachytherapy 2001. London: Arnold, 81-102 |
| Rieke J, Wust P, Stohlmann A et al. | CT guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: Phase I-II results of a novel technique. | Int J Radiat Oncol Biol Phys 2004; 58:1496-1505 |
| Kraus-Tiefenbacher et al. | Long-term toxicity of an intraoperative radiotherapy boost using low energy x-rays during breast-conserving surgery. | Int J Radiat Oncol Biol Phys 2006; 66: 377-381 |
| Peters N, Wiensers G, Pech M et al. | CT-Guided Intersitial Brachytherapy of Primary and Secondary Lung Malignancies. Results of a Prospective Phase II Trial. | Strahlenther Onkol 2008; 184: 296-301 |
| Wiensers G, Mohriike K, Peter N et al. | Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study. | RadiotherOncol2011; 100: 314-319 |
| Grimm P et al. | Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostata Cancer Results Study Group. | BJU Int 2012; 109 (suppl): 22-29 |
| Davis BJ et al. | American Brachytherapy Society consensus guidelines for transrectal ultrasound guided permanent prostate brachytherapy. | Brachytherapy 2012; 11: 6-19 |
| Tsalis N, Chalikastanielou G, Kolotas C et al. | Computed tomography-guided interstitial high dose rate brachytherapy for centrally located liver tumours: a single institution study. | EurRadiol 2013; 23: 2264-2270 |

3. Practical experiences are discussed obtained in clinical studies, (and)
4. Selective references from the literature are provided, (as well as)
5. Representative cases are reported.

General Treatment-associated Data

For an adequate, case-specific decision-making with regard to an appropriate indication and competent realization of the majority of BT, a confident interdisciplinary collaboration is basically required. In particular, this is important for the interstitial application (iBT), e.g.
1. Under ultrasound, CT or MRT guidance tumor lesion is larded with BT catheters (or)
2. Applicators are inserted into whole spaces under CT or ultrasound guidance (or)
3. After tumor debulking or postoperative imaging of the residual tumor lesion, catheters are placed within the tumor bed.

The conceptual idea is to
- achieve a maximally possible, i.e., acceptable tumor-damaging radiation (dose) but,
Simultaneously,
- minimize radiation-induced side effects (e.g., irritable bowel syndrome, skin reaction etc.)

With curative, adjuvant, additive or palliative intention as well as the most promising fractionation modus (one session up to 30Gy, fractionation with 2 radiation sessions per day up to an overall dosage of 30-36Gy) by placement of local radiation sources via various access routes.

The interdisciplinary teams comprise radio oncologists, general and abdominal surgeons, otorhinolaryngologists, oral and maxillofacial surgeons, gastroenterologists, gynecologists, pulmologists and, in particular, interventional radiologists.

Overall Survey of Treatment Data

From 04/2006 to 12/2013, the number of BT increased steadily until 2009 and since then, it has been consolidated.

On average, 330-350 patients per year are currently treated, several of them with oligometastasized status are treated at various tumor sites resulting in a number of procedures (with regard to the treated tumor manifestation sites) of approximately 450.

The mean age of patients was 63.94 (range, 15-89) years; sex ratio (F:m) of iBT patients was 38.4:61.6% (overall including gynecological BT, 55.0:45.0%).

Out of the 2,278 patients treated until 12/2013,
- 56 % underwent iBT of the liver, lung etc.
- 36% were transferred from gynecological departments for an intraluminal, partially also additional Interstitial BT of the genitals,
- 8% were treated with interstitial BT or via moulages at tumor sites of otorhinolaryngology, with Intraluminal (endobronchial, esophageal, anal or endobiliary) BT (and)
- 1% underwent intraoperative radiation using the INTRABEAM device (Carl ZeissMeditec AG, Jena, Germany).

A substantial proportion of the iBT patients underwent multiple BT sessions at various tumor manifestation sites, finally resulting in a number of single applications of 3,117.
The comparison with data from the literature is almost not possible since the proportion of iBT for the treatment of metastases within various organs (lung, liver, kidney etc.) at the reporting institution is extraordinarily high.

The usually provided “standard” BT comprises (as mentioned above) mainly
- Prostate-associated HDR-BT or seed implantations,
- Gynecological and intraluminal applications (and)
- Interstitial treatment of tumor recurrence lesions, e.g., of breast cancer (Table 1).

Medical Discipline and Diagnosis-specific Treatment Experiences

Gynecology

Gynecology belongs to the classical field of this mode of radiotherapy to use BT in malignant gynecological diseases. Dominici is one of the pioneers in the field who worked first with radium capsules implanted intrauterinely in endometrial cancer [35]. Subsequently, intracervical and intrauterine applicators were developed and implanted [36-40].

Today, adjuvant vaginal BT depending on tumor stage according to FIGO classification alone or in combination with EBRT (BT, in particular, to reduce the risk for recurrent tumor growth at the vaginal stump) in endometrial cancer [41-43] as well as intracervical/interstitial application as part of definitive radiochemotherapy of cervical cancer [44,45] belong to standardized treatment protocols.

In addition, BT alone or in combination with percutaneous radiation and simultaneous chemotherapy can also be used, e.g.,
- In primary tumor lesions of the vagina [46-48] (or)
- In vulvar cancer for a preoperative or adjuvant therapeutic setting or as definitive treatment [49-51] predominantly with curative intention.

Through the investigation period, overall
- 474 patients with gynecological tumor lesions (except breast cancer) with 1,626 BT fractions were treated,
  * out of them, 85 patients with primary, inoperable cervical cancer,
  - 358 endometrial cancer patients (and)
  - 31 cases with vaginal or vulvar cancer or recurrent tumor growth of uterine neoplasms.

Head-and-neck tumor lesions

Tumor lesions of the head and neck can be considered a heterogeneous group of patients; therefore, a uniform superordinated treatment concept cannot be easily defined. Currently, there is only a German S3-guideline existing for floor-of-mouth cancer [55], however, there has been a study-based consensus with regard to the role of percutaneous radio-/radiochemotherapy with adjuvant and definitive intention [56-58].

In contrast, a possible interstitial BT without external beam radiation therapy (EBRT) or boosting is frequently not discussed or offered though BT has a substantial value based on several studies [59] with regard to local tumor control and improvement of the overall prognosis [60]. The GEC-ESTRO group (Groupe Européen de Curiethérapie and the European Society for Radiotherapy & Oncology) recommends, therefore, using BT at head and neck [61].

Basically, BT can be used in the following situations:
1. As alternative for surgical resection of locally restricted T1/2 tumor lesions, in particular, at the lips, cheeks and oral cavity [62-64],
2. As addition to percutaneous radiation providing a local dosage escalation in advanced inoperable tumor lesions or after R1 resections and lack of a promising option for repeated resection [65] (and)
3. In recurrent tumor growth at the local tumor site or within lymph nodes and in patients pretreated with
Percutaneous radiotherapy [66–70].

At the University Hospital of Magdeburg (Germany), locally restricted tumor lesions are usually resected, boosting is used via percutaneous access route due to the available modern radiotherapy techniques (e.g., tomotherapy, intensity-modulated radiotherapy=IMRT).

Derived from this, HDR-BT has been predominantly offered to and used in cases with recurrent tumor growth or with palliative intention as well as with previous radiotherapy. Overall, 18 patients were treated from 06/2006 to 12/2013 (Figure 1-7).

-5 after patient-made production of individual moulages,
-13 after surgical intervention aiming for tumor-debulking and in unrespectable tumor growth, respectively,

With interstitial BT. The doses varied from 20 to 36Gy with single doses of 2.5-3Gy twice a day and a minimal interruption of 6 hours between the single fractions.

Brachytherapy in intraluminal tumor lesions

Intraluminal BT applications may reasonably add multimodal treatment concepts with curative or palliative intention [71,72]. In the following tumor sites, BT has been proven:

- Bronchial [73–75],
- Esophageal [76, 77],
- Biliary[78,79] (and)
- Anal [80].

BT plays, in particular, an additional role to the
- Primary surgical approach,
- Percutaneous radiation,
- Combination with palliative chemotherapy, and
- Palliative intention in pretreated patients with percutaneous radiotherapy.

At the reporting institution, overall 21 patients underwent BT at the tumor sites as listed above from 2006 to 2013:

- The largest proportion comprised patients with recurrent tumor growth of esophageal cancer,
- 4 cases with locally restricted but despite this unrespectable cholangiocarcinoma (and)
- The remaining cases were successfully treated with palliative intention aiming for local tumor control.

Interstitial brachytherapy (iBT) for treatment of local tumor lesions and metastases.

In addition to the described indications, metastases within parenchymatous organs (liver, lung, and kidney) or even soft tissue and lymph node metastases are suitable for iBT. In detail, needles or BT catheters are precisely inserted – either intraoperatively or under CT- or MRT-based fluoroscopy guidance - into malignant tumor masses. Using this approach, lower numbers of thoracic/pulmonary, hepatic or abdominal metastases but also primary livertumors or soft tissue sarcomas can be treated.

Feasibility, safety and benefit of this minimally invasive type of radiation has been proven by numerous retro- and prospective studies and analyses in the mean time [26,31,81,82], which thus occupies an established place in the reporting department.

This has become possible by the close collaboration with interventional radiologists and all the transferring oncological disciplines in medicine, in particular, with abdominal surgery.

Primary aim was to achieve local symptom control by radiation-induced cytoreduction with palliative intention at the beginning [26] but the study results showed that in numerous cases, a sustainable local control sometime even an improvement of the overall prognosis became possible.

In the phase-II study by Ricke et al. [83], local control rate after iBT of overall 73 patients (subdivided into three various groups of doses (one-time doses per group: 15, 20 or 25 Gy)) with 199 hepatic metastases of colorectal cancer in total was investigated. The mean local control rate of all groups was 34 months(according to Kaplan–Meier assessment) whereby it significantly increased – as expected – with higher dose of radiation (25.6, 31.1 and 46.6 months, respectively). Mohnike et al [84]. Showed a significantly better survival in 83 patients with HCC who had undergone prospective BT compared (by "matched-pair" analysis) with a group of patients with no radiation.

A further study reported on local 1- and 2-years control rates of 93% and 82% in secondary and 86% and 79%, respectively, in primary solitary but unrespectable malignant neoplasms of the lung [85].

**Representative Case Reports**

**Case 1 (Figures 8-11)**

Medical history: 74-year old male patient with symptomatic metastasis of rectal cancer localized at the left iliac muscle.

10/2006 – deep anterior resection with TME and creation of a protective ileostoma, pT3a pN1 (14/81) cM0 R0 G2

Until 04/2007 – adjuvant radio chemotherapy with 5-FU ad 54 Gy
followed by 4 cycles of Chemotherapy alone with 5-FU

06/2007 – Recreation of gastrointestinal passage

01/2011 – Recurrent tumor growth at the left iliac muscle

Until 04/2012 – 2nd and 3rd line chemotherapy

- Result: partial response
- Side effect: polyneuropathy and -foot syndrome

05/2012 – local radiotherapy because of pain ad 14.4Gy – result: “Stable disease” (SD)

12/2012 – subsequently SD but increasing pain.

Therapeutic decision-making after interdisciplinary board presentation of the case: Surgical intervention aiming for a possibly radical but function-preserving tumourreduction and following local BT taking into account the previous radiation exposition and dose.

Further clinical course:

03-04/2013 – Tumor debulking+ postoperative fractionated iBT ad 18/6 Gy at the R2 site

10/2013 – distinct reduction of the treated tumor volume and the pain, advanced tumor growth at the peripheral site of the treated tumor region

11/2013 – repeated, locally restricted one-time iBT taking into account the exposure due to pre-radiation ad 13Gy

08/2014 – Recurrent tumor growth within the surrounding tissue with infiltration of the right ileal Bone: “Involved-field” EBRT taking into account the exposure due to pre-radiation ad 20/4 Gy.

Result: At the time of increasing symptoms, patient denied repeated chemotherapy because of the persisting side effects. Since distant metastases could be excluded, a local ablation appeared reasonable. High-dose iBT allowed – after surgical R2 tumor resection – a completion of ablation.

Because of the 2-times prior percutaneous charge, repeated EBRT would have been associated with significantly higher risk of a damage of surrounding risk structures (OAR) and lower effectivity (fractionation).

Furthermore, locally restricted iBT allowed a repeated radiation therapy of the neighboring regions which showed metastases during further clinical course.

Final assessment: Overall, a distinct improvement of the partially considerable symptoms could be achieved by an interdisciplinary coordinated local therapy.

Case 2 (Figures 10-12)

Medical history: 33-years old patient with superior vena-cava compression syndrome due to a synovial cell sarcoma with metastases in the lung and lymph nodes, G III.

09/2004 Solitary primary tumor lesion at the left heel leading to amputation of the left calf

12/2005 Primary diagnosis of pulmonary metastases leading to right-sided segmental resection

11/2005-02/2006 3 cycles of chemotherapy with Ifosfamid/Adriamycin

02/06 Stereotactic RT ad 30 Gy per single dose of 10 Gy because of recurrent tumor growth within the left paracardial region
perspective, this procedure preserves risk structures (such as rectum, time period of approximately 3 months. From a radiobiological characteristic feature of the seeds is the slow emission of energy. This procedure is, therefore, called "Low-Dose-Rate brachytherapy" (LDR).

intraoperative radiation of the tumor bed in recurrent tumor growth further indications are under close examination, among others, patients with metastases of colorectal origin [83] but also those with locally restricted HCC [34,84] may benefit from this approach with a prolongation of survival. A basic prediction for the patients with BT of hepatic neoplasms. These patients underwent dependency on the tumor entity single doses spanning from 15 to 20 Gy.

Since the patient favored a possibly short hospital stay, option (b) was performed. Taking into account the OAR, the tumor parts close to the vena cava, which caused superior vena-cava compression syndrome, were treated with radiotherapy of a surrounding dose (D100) of 9.5 Gy (D95: 15 Gy, D90: 16 Gy).

Result: After three days, reduction of the symptoms of the superior vena-cava compression syndrome; patient was discharged after four days. Control CT scan approximately four weeks post radiation revealed a favorable PR with a free patency through the superior vena-cava segment, radiogenic side effect were not seen, in particular, no radiation-induced pneumonitis.

Final assessment: This case indicates the benefit of an only cytoreductive interstitial BT. In an overall limited prognosis due to total tumor burden, a prompt and effective control of the partially severe symptoms could be achieved.

Outlook (Further in Near Future Available Approaches and Procedures)

Since February 2012, a further approach of "short brachytherapy" has been offered, which is – however – not considered a mode of classical BT but finally based on the emission of a low-energy X-ray, it preserves surrounding structures and organs effectively. The device is called INTRABEAM® (Carl Zeiss Meditec AG, Oberkochen, Germany).

Primarily, patients with breast cancer benefit from it [86,87], further indications are under close examination, among others intraoperative radiation of the tumor bed in recurrent tumor growth of neoplasms of the pelvis.

In addition, since 2014 insertion of radioactive seeds in locally restricted tumor lesions of the prostate has been offered. The characteristic feature of the seeds is the slow emission of energy. This procedure is, therefore, called "Low-Dose-Rate brachytherapy" (LDR). Tumor-damaging dose of energy is continuously emitted over a time period of approximately 3 months. From a radiobiological perspective, this procedure preserves risk structures (such as rectum, urinary bladder) better than conventional EBRT would be able to.

Disadvantages, Side Effects, Complications of Brachytherapy and their Management

A potential disadvantage of iBT is the invasiveness, which – however – is minimal but can be considered a still existing risk for bleedings, infections or – in the treatment of pulmonary metastases – for pneumothorax. Tselis et al. investigated the rate of acute side effects after hypo fractionated iBT of unrespectable primary and secondary hepatic metastases close to the hilus in 41 patients. The incidence for grade-III/-IV side effects was 5% [88].

A comparable result indicating a rate of severe grade-III/-IV side effects lower than 5% was reported by Mohnike et al. (manuscript submitted) in a retrospective analysis of a patient cohort of 192 patients with BT of hepatic neoplasms. These patients underwent depending on the tumor entity single doses spanning from 15 to 20 Gy.

Taken together, the retrospective studies as well as the data obtained in prospective studies at Magdeburg, Berlin and Offenbach (Germany each; as cited above) indicate that iBT can be considered locally ablating tumor therapy with high effectivity and a low rate of side effects if the known and newly validated dose limitations are carefully respected [89-91].

By means of specific institutional "standard operating procedures", which define clearly preparation, interventional procedure and post interventional monitoring as well as risk management, the majority of complications has been micro invasively and conservatively treated since 2006.

Discussion

The value of radiotherapy established until today as part of curative and palliative tumorthereapy strategies cannot longer denied even if the use of it is possibly ranked inferior to best supportive care and beyond primary therapeutic concepts in a certain proportion of oncologists.

While the options of percutaneous radiation techniques are known and present as well as discussed in the media and tumor board conferences throughout the country, BT is rather underestimated.

However, advantages are obvious in case of a clearly defined indication, e.g.

- High, locally applicable tumor-damaging dose,
- Better preservation of the surrounding OAR by a steep dose gradient (and)
- Shorter hospital stay, since over a few days a sufficient dose can be applied.

In the mean time, pro- and retrospective studies provided evidence that in part more than a palliative effect can be achieved. In particular, patients with metastases of colorectal origin [83] but also those with locally restricted HCC [34,84] may benefit from this approach with a prolongation of survival. A basic prediction for the broad use of brachytherapeutic interventions is an interdisciplinary collaboration.
-Adapted to patients’ needs and tumor-specific finding(s),
-Related to the specific tumor entity and stage,
-According to established therapeutic experiences and proven modi of radiation to exhaust a sufficient, (neo-) adjuvant, additive or palliative therapeutic effect.

In addition, it has been shown that in many cases BT can be considered– from the perspective of health economy–a cost-effective but despite this a highly effective treatment alternative in the age of a rather increasingly cost-intensive tumor therapy, which broadens the spectrum of radio oncology.

**Conclusion**

Gold standard of local ablation was and is surgical resection. A certain percentage of (oligo-) metastasized patients can not undergo surgical intervention or tumor mass is unrespectable from a functional and tumor biological perspective. These patients can nevertheless treated with local ablation since in addition to surgical intervention (resection), there has been a number of non- and minimally invasive techniques available. These procedures can be subdivided into thermo-, chemo- and radio-ablating methods and have been multiply proven in prospective and retrospective studies with regard to safety, effectiveness and side effect rate [92-100].

RFA is currently the best validated method, which – if the metastasis is not bigger than 3cm in diameter – can be, in particular, in the liver, and is considered a reasonable alternative to surgical resection resulting in a very similar, i.e., low tumor recurrence rate (3.5 vs. 6 % per lesion). In larger metastases, surgical resection is superior (7.4 vs. 14.5 %) [101]. Under these circumstances iBT used in radiotherapy routine for decades can reasonably add the spectrum of indications and therapeutic modalities.

Data obtained in phase-II studies showed that in case of sufficient tumor-surrounding dose application, local tumor recurrence rate is approximately.

- 6.5 % in liver metastases of breast cancer [82],
- 5 % in liver metastases of colorectal origin [83] (and)
- 9 % and 14 / 7 % in primary and secondary malignant neoplasms of the lung [85].

In addition, Mohniket al. [32] was able to demonstrate a significant improvement of survival in patients with versus cases without BT of locally advanced HCC manifestation.

A successful iBT requires a close interdisciplinary cooperation between radio oncologists, interventional radiologists and all oncological disciplines in medicine.

Finally, the clue for a broad use of all available oncological therapeutic options is their profound knowledge on
- the appropriate indications and possible complications,
- the indicated differential therapy,
- Methodological strengths and weaknesses obtained from individual

* Case-based experiences (and)

**References**

1. Röntgen WC. Ueber eine neue Art von Strahlen. Vorläufige Mittheilung. Sonderabdruck aus den Sitzungsberichten der Würzburger Physik.-medic. Gesellschaft 1895, Verlag: Stahel’sche K. Hof- und Universitätsbuch- und Kunsthandlung oder 2. Aufl. Wurzburg. 1896.

2. Becquerel H. Emissions of the new radiations by metallic uranium. Comp Rend Acad Sci. 1896; 122:1086.

3. Becquerel H, Curie P. Action physiologiques des rayons du radium. C R AcadSci Gen.1901; 132: 1289–1291.

4. Curie P, Curie M. Sur une substance nouvelle radio-active contenue dans la pechblende. C R AcadSci Gen. 1898; 127: 175–178.

5. Freund L. Ein mit Röntgenstrahlen behandelte Fall von Naevuspigmentosispiliferos. Wien Med Wochensch. 1897; 10: 428–433.

6. Morton R. Treatment by Roentgen– and radium rays. BrMedJ. 1904; 1: 941–944.

7. Pusey WA Caldwell EW. The practical applications of the Roentgen rays in therapeutics and in diagnosis. 2nd edn Philadelphia: Saunders, 1904.

8. Wickham L, Degrais P. Die Radiumbehandlung des Krebses. Fortschritte auf dem Gebiel der Röntgenstrahlen. 1910; 16: 73.

9. Wickham L, Degrais PN.Kanndas Radium der Chirugie bei derBehandlungmalignerTumorenDienstleisteten? Strahlentherapie. 1913; 3: 457–472.

10. Wickham L, Degrais P. Radium as employed in the treatment of cancer, angiomata, keloids, local tuberculosis and other affections. New York: Paul B. Hoeber; 1913.

11. Goldberg SW, London ES. Zur Frage der Beziehungen zwischen Beugereistrahlen und Hautaffektionen. Dermatol Z. 1903; 10: 457–462.

12. Strebek H. Vorschläge zur Radium Therapie. Dtsch Med Z.1903; 24: 1145-1146.

13. Abbé R. The status of radium. Med Rec (New York).1904; 65: 356.

14. Strebek H. Der gegenwärtige Stand der Radiumforschung. Zeitschrift für neuere physiologische Medizin. 1908; 15: 180-183.

15. Wolff KD, Book F, Beck J, et al. S3 Leitlinien Mundhöhlenkarzinom. Leitlinienprogramm Onkologie der AWMF.

16. Bartelink H, Roelofsen F, Eschwege F, Rouquier P, Bossert JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of phase III randomized trial of the EORTC Radiotherapy and Gastrointestinal Cooperative Group. J ClinOncol.1997; 15: 2040–2049.

17. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostata Cancer Results Study Group, BJU Int. 2010; 109: 129-22.

18. Colombo N, Carinelli S, Colombo A, et al. on behalf of the ESMO Guidelines Working Group. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23: 27-32.

19. Rentsch M, Winter H, Bruns CJ, et al. Cyberknife®-Chirurgie mit dem Strahlenmesser: eine neue Behandlungsalternative für Patienten mit inoperablen Metastasen. ZentralbChir. 2010; 135: 175–180.

20. Dudeck O, Weigt J, Schubert D, et al. Deutsche Akademie für Mikrotherapie (DAfMT) - moderne bildgeführte, minimalinvasive, mikrotherapeutische, teils interdisziplinäre Therapieansätze zur klinischen Ausbildung & für die Praxis (Nachlese zum Eröffnungssymposium zu Ansatz, Zielstellung, Spektrum & Umsetzungskonzepte), Zentralb Chir. 2011; 136: 634–635.

21. Damm R, Seidensticker R, Rieke J, et al. Interventional Radiological Procedures in the Therapy for Colorectal Liver Metastases. ZentralbChir. 2013; 138: 76–83.

*Case presentations at tumor board conferences.
22. Bleicher RJ, Allegra DP, Nora DT, et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol. 2003; 10: 52–58.

23. Ruers T, Punt CJ, van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004): Ann Oncol. 2012; 3: 2619–2626.

24. Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014; 270: 900–909.

25. Cucchetti A, Piscaglia F, Cescon M, et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis. 2014; 46: 257–263.

26. Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J VascIntervRadiol. 2004; 15: 1279–1286.

27. Colletti F, Golenia M, Schnapauß D, et al. Percutaneous computed tomography-guided high-dose-rate brachytherapy ablation of breast cancer liver metastases: Initial experience with 80 lesions. J VascIntervRadiol. 2012; 23: 618-626.

28. Bretschneider T, Peters N, Hass P, et al. Update interstitielle Brachytherapie. Radiologe. 2012; 52: 70–3.

29. Hass P, Bretschneider T, Mohnike K. CT-guided brachytherapy. Interventionielle Rad Scan. 2013; 2: 163-180.

30. Schnapauß D, Denecke T, Grieser C, et al. Computed Tomography-Guided Intersitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Inresectable Intrahepatic Cholangiocarcinoma. CardiovascIntervRadiol. 2012; 35: 581–587.

31. Peters N, Wieners G, Pech M, et al. CT-guided interstitial brachytherapy of primary and secondary lung malignancies. Results of a prospective phase II trial. Strahlentherapie. 2008; 184: 296-301.

32. Mohnike K, Wieners G, Pech M, et al. Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. Dig Dis. 2009; 27: 170–176.

33. Ricke J, Wust P. Computed Tomography-Guided Brachytherapy for Liver Cancer. SeminRadiatOncol. 2011; 21: 287-293.

34. Colletti F, Schnapauß D, Poelfinger A, et al. Hepatocellular carcinoma: computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours. EurRadiol. 2012; 22: 1101–1109.

35. Dominici H, Barcat J. Des modifications histologigues determines par le rayonnement du radium. Arch elec med. 1907; 15: 835-836.

36. Forsell G. Übersicht über die Resultate der Krebsbehandlung am Radiumhemmet in Stockholm 1910-1915. FortschrRontgenstr. 1917; 25: 142-149.

37. Collez R. Les bases physiques de l’irradiation du cancer du col uterin par la curietherapie la radiotherapie. J Radiol. 1923; 7: 201-216.

38. Heyman J. Radiological or operative treatment of cancer of the uterus. ActaRadiol. 1927; 8: 363-409.

39. Lacassagne A. Results of the treatment of cancer of the cervix uteri. Br Med J. 1932; 2: 912-913.

40. Heyman J. The radiuhammet method of treatment and results in cancer of the corpus uteri. JObstet Gynecol. 1936; 43: 655-666.

41. Knocke TH, Tatztreiter G, Baldas M, et al. Results of postoperative irradiation in Patients with high risk endometrial carcinoma. RadiotherOncol. 1998; 48: 66.

42. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: multicenter randomized trial. PORTEC Study Group. Postoperative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355: 1404-1411.

43. Klop A, Smith, BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncol. 2014; 4: 137-144.

44. Thomas G. Improved treatment for cervical cancer – Concurrent chemotheraphy and radiotheraphy. N Engl J Med. 1999; 340: 1198-1200.

45. Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. RadiotherOncol. 2005; 74: 235-245.

46. Chyle V, Zagers GK, Wheeeler JA, et al. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J RadiatOncolBiol Phys. 1996; 35: 891-905.

47. Tewari KS, Cappuccini F, Puthawala AA, et al. Primary invasive carcinoma of the vagina: Treatment with interstitial brachytherapy. Cancer. 2001; 91: 758-770.

48. Dimopoulos J, Schmid M, Berger D et al. MRI-guided Brachytherapy with external beam therapy plus chemotherapy for the treatment of locally advanced vaginal cancer. RadiotherOncol. 2009; 1: 51.

49. Kumar PP, Good RR, Scott JC. Techniques for management of vulvar cancer by irradiation alone. Radiat Med. 1988; 6: 185-191.

50. Pohar S, Hofstetter S, Peiffert D, et al. Effectiveness of brachytherapy in treating carcinoma of the vulva. Int J RadiatOncolBiol Phys. 1995; 32: 1455-1460.

51. Seeger AR, Windschall A, Lotter M, et al. The role of interstitial brachytherapy in treatment of vaginal and vulvar malignancies. Strahlentherapie. 2006; 182: 142-148.

52. Paterson R, Parker HM. A dosage system for interstitial radium therapy. Br J Radiol. 1938; 1: 252-340.

53. Meredith WJ. Radium Dosage: The Manchester System. Edinburgh: Livingston. 1967.

54. Henschke U, Hiliaris BS, Mahan GD. Afterloading in interstitial and intracavitary radiation therapy.Am J Roentgenol.1963; 90: 386-395.

55. Wolff KD, Boott F, Beck J, et al. Leitlinienprogramm Onkologie / S3-Leitlinie Mundhöhlenkarzinom. September 2012; AWMF-Register 007-1000L, Version 2.0.

56. Al-Sarraf M, Pajas TF, Byhardt RW, et al. Postoperative radiotherapy with concurrent cisplatin appears to improve loco regional control of advanced, respectable head and neck cancers: RTOG 88-24. Int J RadiatOncolBiol Phys. 1997; 37: 777-782.

57. Pignon JP, Bouthis J, Domenge C, et al. Chemotherapy added to loco regional treatment for head and neck squamous cell carcinoma: Three metaanalyses of updated individual data. MACH-NCCollaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355: 949-955.

58. Pignon JP, le Malffe A, Maillard E, et al. on behalf of the MACH-NCCollaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An updateon 93 randomised trials and 17346 patients. RadiotherOncol. 2009; 92: 4–14.

59. Zelefsky MJ, Zimberg SH, Raben A, et al. Brachytherapy for locally advanced and recurrent lymph node metastases. J Brachytherapy Int. 1998; 14: 123-130.

60. Gerbaulet A, Maher M. Brachytherapy in the treatment of head and neck cancer. In: Joslin CAF, Flynn A, Hall EJ (eds). Principles and practice of high dose rate brachytherapy 2001. London: Arnold; 284-295.

61. Mazeron JJ, Ardit JM, Haie-Meder C, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. RadiotherOncol. 2009; 162: 235-245.

62. Takehira I, Toshihiko I, Teruki T, et al. Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. Int J RadiatOncolBiol Phys. 1996; 36: 1201-1204.
63. Grabenbauer GG, Rödel C, Brunner T, et al. Interstitial brachytherapy with Iridium-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997. Strahlenther Onkol. 2001; 177: 338-344.

64. Guinot JL, Arrimbas L, Vendrell JB, et al. Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate Brachytherapy. Head Neck. 2013; 36: 1737-1742.

65. Nag S, Cano ER, Demanes DJ, et al. for the American Brachytherapy Society. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiation Oncol Biol Phys. 2001; 50: 1190-1198.

66. Syed AM, Feder BH, George FW 3rd, et al. Iridium-192 afterloaded implant in the retreatment of head neck cancers. Br J Radiol. 1978; 51: 614-620.

67. Stmad V, Geiger M, Lotter M, et al. Role of brachytherapy for head and neck cancer: retreatment in previously irradiated area. Brachytherapy. 2003; 2: 158-163.

68. Narayana A, Cohen GN, Zaider M, et al. High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers: preliminary results. Brachytherapy. 2007; 6: 157-163.

69. Rudzianksas V, Incuara A, Juozaityte E, et al. Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy. ACTA otolaryngologica. 2012; 32: 297-303.

70. Tsels N, Ratka M, Vogt HG, et al. Hypofractionated accelerated CT-guided interstitial 192Ir-HDR-Brachytherapy as reirradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. Radiother Oncol. 2011; 98: 57-62.

71. Nag S. Principles and practice of brachytherapy 1997. New York: Futura Publishing Company.

72. Speiser BL, Mould RF. Brachytherapy for the 21st century. Veenendaal The Netherlands: Nucletron International. 1998.

73. Gejerma G, Mullikandan EA, Bagiella E, et al. Endobronchial brachytherapy and external-beam radiotherapy in patients with endobronchial obstruction and extrabronchial extension. Brachytherapy. 2002; 1: 2004-2010.

74. Morris CD, Budde JM, Godette KD, et al. Palliative management of malignant airway obstruction. Ann Thorac Surg. 2002; 74: 1928-1933.

75. Manali ED, Stathopoulos GT, Gildea TR, et al. High-dose-rate endobronchial radiotherapy for proximal airway obstruction due to lung cancer: 8-year experience of a referral center. Cancer Biother Radiother. 2010; 25: 207-213.

76. Hareyama M, Nishio M, Kagami Y, et al. Intracavitary brachytherapy combined with external beam irradiation for squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys. 1992; 24: 235-240.

77. Lettmäier S, Stmad V. Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique. J Contemporary Brachytherapy. 2014; 6: 236-241.

78. Välek V, Kysela P, Kala Z, et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol. 2007; 62: 175-183.

79. Shinhohara ET, Guo M, Mitra N, et al. Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2010; 78: 722-728.

80. Shrivastava SK, Engeneer R, Mahantshetty U, et al. External beam radiotherapy and interstitial brachytherapy with or without chemotherapy in the conservative treatment of anil carcinoma. Brachytherapy. 2008; 7: 102.

81. Ricke J, Wust P, Stohlmann A, et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys. 2004; 58: 1496-1505.

82. Wiemers G, Mohnike K, Peters N, et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study. Radiother Oncol. 2011; 100: 314-319.

83. Ricke J, Mohnike K, Pech M, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010; 78: 479-485.

84. Mohnike K, Wiemers G, Schwartz F, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: Safety, efficacy and effect on survival. Int J Radiation Oncology Biol Phys. 2010; 78: 172-179.

85. Tsels N, Ferentinos K, Kolotas C, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011; 6: 545-552.

86. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomized, non-inferiority phase 3 trial. Lancet. 2010; 376: 91-102.

87. Kraus-Tiefenbacher U, Herrmann B, Siebenlist T, et al. Long-term toxicity of an intraoperative radiotherapy boost using low energy x-rays during breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2006; 66: 377-381.

88. Tsels N, Chatzikonstantinou G, Kolotas C, et al. Computed tomography-guided interstitial high dose rate brachytherapy for centrally located liver tumours: a single institution study. EurRadiol. 2013; 23: 2264-2270.

89. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation Int J Radiat Oncol Biol Phys. 1991; 21: 109–122.

90. Streltparsh F, Pech M, Bohmig M, et al. In vivo assessment of the gastric mucosal tolerance dose after single fraction, small volume irradiation of liver malignancies by computed tomography-guided, high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2006; 65: 1479-1486.

91. Marks L, Yorke ED, Jackson E, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010; 76: 10–19.

92. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unrespectable chemoradio refractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology. 2008; 247: 507-515.

93. Ricke J, Großer O, Amthauer H. Y90-radioembolization of lung metastases via the bronchial artery: a report of 2 cases. CardiovascInterventRadiol. 2013; 36:1664–1669.

94. Lee DH, Lee JM, Lee JY et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014; 270: 900–909.

95. Weis S, Franke A, Mösner J, et al. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2013.

96. Pech M, Wiemers G, Freund T, et al. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patients survival. Eur J Med Res. 2007; 12: 161-168.

97. Bruix J, Sala M, Llovet JM. Chemoembolisation for hepatocellular carcinoma. Gastroenterology. 2004; 127: 179-188.

98. Schefter TE, Kevanagh BD. Radiation therapy for liver metastases. SeminRadiation Oncol. 2011; 21: 264-270.

99. Navarria P, Ascolese AM, Tomatis S, et al. Stereotactic body radiotherapy (SBRT) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014; 9: 91.

100. Hass P, Mohnike K. Extending the frontiers beyond thermal ablation by RFA: SBRT, Brachytherapy, SIRT: Visceralmedizin. 2014; 30: 245-252.

101. Tanis E, Nordlinger B, Mauer M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 2014; 50: 912–919.